Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Aclaris Therapeutics (ACRS)
NASDAQ:ACRS
RESEARCH TOOLSreports
Aclaris Therapeutics (ACRS) Stock Price & Analysis
565 Followers
ACRS Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$0.59 - $11.12
Previous Close$1.15
Volume653.21K
Average Volume (3M)836.49K
Market Cap
$81.95M
Enterprise Value-$36.73M
Total Cash (Recent Filing)$119.11M
Total Debt (Recent Filing)$426.00K
Price to Earnings (P/E)―
Beta1.10
Next Earnings
Aug 08, 2024EPS Estimate
-$0.2Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.09
Shares Outstanding71,264,786
10 Day Avg. Volume698,273
30 Day Avg. Volume836,489
Standard Deviation0.39
R-Squared0.00009
Alpha0.03
Financial Highlights & Ratios
Price to Book (P/B)0.52
Price to Sales (P/S)2.62
Price to Cash Flow (P/CF)-3.00
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue-1.21
Enterprise Value/Gross Profit-2.79
Enterprise Value/Ebitda0.39
Forecast
1Y Price Target
$2.00Price Target Upside75.44% Upside
Rating ConsensusHold
Number of Analyst Covering2
Aclaris Therapeutics News
PremiumCompany Announcements
Aclaris Therapeutics Corporate Update Conference Call
PremiumCompany Announcements
Board Changes Ahead of Aclaris Therapeutics Annual Meeting
PremiumCompany Announcements
Aclaris Therapeutics Executive Team Undergoes Major ChangesBulls Say, Bears Say
Bulls Say
Cash PositionAclaris has a strong cash position, believed to be sufficient to fund operations for the next few years.
Clinical TrialsACRS reported positive Phase 1 MAD data in healthy volunteers showing '2138 to be well-tolerated, and demonstrating a dose-dependent inhibitory effect on ITK and JAK3.
Financial PerformanceAclaris reported a smaller net loss per share than originally forecasted, indicating better financial performance than expected.
Bears Say
Analyst RatingAnalyst reiterates a Neutral rating without a price target, pending further clarity on the development of the company's pipeline assets.
Clinical DataACRS initiated a company-wide strategic review following disappointing clinical data from zunsemetinib in RA and HS, where both studies failed to achieve primary and key secondary endpoints.
CommercializationThe company is still seeking a partner to out-license worldwide rights for ATI-1777, indicating potential uncertainty in the commercialization process.
---
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
ACRS FAQ
What was Aclaris Therapeutics’s price range in the past 12 months?
Aclaris Therapeutics lowest stock price was $0.59 and its highest was $11.12 in the past 12 months.
What is Aclaris Therapeutics’s market cap?
Currently, no data Available
When is Aclaris Therapeutics’s upcoming earnings report date?
Aclaris Therapeutics’s upcoming earnings report date is Aug 08, 2024 which is in 36 days.
How were Aclaris Therapeutics’s earnings last quarter?
Aclaris Therapeutics released its earnings results on May 07, 2024. The company reported -$0.24 earnings per share for the quarter, beating the consensus estimate of -$0.286 by $0.046.
Is Aclaris Therapeutics overvalued?
According to Wall Street analysts Aclaris Therapeutics’s price is currently Undervalued.
Does Aclaris Therapeutics pay dividends?
Aclaris Therapeutics does not currently pay dividends.
What is Aclaris Therapeutics’s EPS estimate?
Aclaris Therapeutics’s EPS estimate is -$0.2.
How many shares outstanding does Aclaris Therapeutics have?
Aclaris Therapeutics has 71,264,786 shares outstanding.
What happened to Aclaris Therapeutics’s price movement after its last earnings report?
Aclaris Therapeutics reported an EPS of -$0.24 in its last earnings report, beating expectations of -$0.286. Following the earnings report the stock price went down -8.955%.
Which hedge fund is a major shareholder of Aclaris Therapeutics?
Among the largest hedge funds holding Aclaris Therapeutics’s share is Aisling Capital Management LP. It holds Aclaris Therapeutics’s shares valued at 539K.
---
Aclaris Therapeutics Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$2.00 (75.44% Upside)
$2.00 (75.44% Upside)
Hedge Fund Trend
Decreased
By 20.0K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $4.1M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Neutral
Last 7 Days ▼ 1.2%
Last 30 Days ▲ 1.4%
Last 30 Days ▲ 1.4%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-88.91%
12-Months-Change
Fundamentals
Return on Equity
-48.47%
Trailing 12-Months
Asset Growth
-24.22%
Trailing 12-Months
Company Description
Aclaris Therapeutics
Aclaris Therapeutics, Inc. operates as a dermatologist-led biopharmaceutical company, which engages in identifying, developing, and commercializing novel drugs to address the needs in medical and aesthetic dermatology and immunology. It operates through Therapeutics and Contract Research segments. The Therapeutics segment focuses in identifying, developing, and commercializing innovative and differentiated therapies to address significant unmet needs in medical and aesthetic dermatology. The Contract Research segment provides laboratory services under contract research arrangements to pharmaceutical and biotech companies. The company was founded by Neal S. Walker, Frank Ruffo, Kamil Ali-Jackson, Christopher V. Powala, and Stuart D. Shanler in July 2012 and is headquartered in Malvern, PA.
---
ACRS Company Deck
---
ACRS Earnings Call
Q1 2024
0:00 / 0:00
---
ACRS Stock 12 Month Forecast
Average Price Target
$2.00
▲(75.44% Upside)
Technical Analysis
Best Analysts Covering ACRS
1 Year
1 Year Success Rate
0/4 ratings generated profit
1 Year Average Return
-87.20%
reiterated a buy rating 11 months ago
Copying Corinne Johnson's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of -87.20% per trade.
---